Follow the Bausch + Lomb Corporation share price and the full directors' dealings record of the company, a listed issuer based in Canada. Shares trade on the CA market, under the supervision of SEDI. Operating in the Health Care sector, Bausch + Lomb Corporation has published 49 reports. Market capitalisation: €8.4bn. The latest transaction was reported on 14 August 2026 (56 - Grant of rights). Among the most active insiders: Munsch, Frederick John. All data is openly available.
49
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Bausch + Lomb Corporation Buy (bullish), based on 1 analysts. Average price target: CA$25.09.
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,295 of 28,958 companies
27.6
score / 100
Value
24
Quality
31
FCF yld-0.8%
Earn yld-4.2%
EV/EBITDA26.0x
ROE-2.5%
Gross mgn60%
Net mgn-7.1%
Debt/EBITDA9.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
700 shares@ CA$16.7850.0001% mcap2.2% of flowCommon SharesTSXSEDI:4763594
Canonical exit: 8 Nov 2026 (T+90)
25 of 49 declarations
About Bausch + Lomb Corporation
Bausch + Lomb Corporation is a company focused on eye health products, including contact lenses and ophthalmic pharmaceuticals. It is listed on the Toronto Stock Exchange under the symbol XTSE.